Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 28

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
(107)(682)Change in fair value of contingent consideration liabilities5,089 3,492 Payments of contingent consideration liabilities(2,184)(1,456)Stock-based compensation798 747 Acquired IPR&D and milestones3,751 1,183 Non-cash litigation reserve adjustments, net of cash payments(1,069)341 Impairment of intangible assets847 — Other, net6 (75)Changes in operating assets and liabilities, net of acquisitions:Accounts receivable(1,652)(180)Inventories(209)(191)Prepaid expenses and other assets(169)461 Accounts payable and other liabilities1,549 (1,070)Income tax assets and liabilities, net(1,408)(1,405)Cash flows from operating activities13,812 11,758 Cash flows from investing activitiesAcquisitions of businesses, net of cash acquired(204)(17,493)Other acquisitions and investments, net of cash acquired(4,076)(1,232)Acquisitions of property and equipment(885)(683)Purchases of investment securities(29)(46)Sales and maturities of investment securities42 516 Other, net(28)(8)Cash flows from investing activities(5,180)(18,946)Cash flows from financing activitiesNet change in commercial paper borrowings with original maturities of three months or less999 — Proceeds from issuance of other short-term borrowings4,798 5,008 Repayments of other short-term borrowings(2,007)(5,008)Proceeds from issuance of long-term debt3,994 14,963 Repayments of long-term debt and finance lease obligations(6,789)(3,851)Debt issuance costs(23)(99)Dividends paid(8,746)(8,273)Purchases of treasury stock(977)(1,350)Proceeds from the exercise of stock options124 204 Other, net69 56 Cash flows from financing activities(8,558)1,650 Effect of exchange rate changes on cash and equivalents31 (19)Net change in cash and equivalents105 (5,557)Cash and equivalents, beginning of period5,524 12,814 Cash and equivalents, end of period$5,629 $7,257 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form